# Derivatives of clavulanic acid, a process for their preparation and their use.

## Abstract
Compounds of formula I

## Claims
CLAIMS 1. A compound of formula I EMI42.1 or a salt or ester thereof wherein R represents a group R1, OR1, SR1 or NRARB, where R1, RA and RB independently represent hydrogen, a substituted or unsubstituted hydrocarbon radical, or RA and RB together form the residue of a heterocyclic ring, X represents oxygen or sulphur and R2 is an optionally substituted hydrocarbon or heterocyclic group. 2. A compound as claimed in claim 1 in the form of the free acid, pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. 3. A compound as claimed in claim l or 2 wherein X represents oxygen. 4. A compound as claimed in any one of claims I to 3 wherein R2 represents a C1 6 group optionally substituted by hydroxy, carboxy, cyano or a carboxylic acid, salt or ester. 5. A compound as claimed in any one of claims l to 4 wherein R represents hydrogen or an optionally substituted hydrocarbon radical of up to 20 carbon atoms. 6. A compound as claimed in any one of claims l to 5 wherein R represents hydrogen, C16 alkyl, C16 alkoxy, C1 6 alkylamino or phenyl optionally substituted with from 1 to 3 substituents selected from C16 alkyl, nitro halogen or hydroxy. 7. A compound as claimed in claim 6 wherein R represents hydrogen. 8. A process for the preparation of a compound as claimed in claim l, which process comprises reacting a compound of formula IV EMI43.1 wherein R2 is as defined in claim 1 and Ra is a hydrogen atom or a carboxy blocking group with an N acylating derivative of an acid of formula EMI43.2 wherein R and X are as defined in claim 1 and optionally thereafter i removing any carboxy blocking group Ra ii converting the product into a salt or ester. 9. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound as claimed in claim 2. 10. A composition as claimed in claim 9 which further comprises an antibacterial agent.

## Description
ss LACTAM COMPOUNDS This invention relates to ss lactam compounds and in particular to a class of clavulanic acid derivatives substituted by an acylamino group. These compounds have antibacterial and ss lactamase inhibitory qualities, and therefore are of use in the treatment of bacterial infection either alone or in a synergistic composition with other antibacterial agents, such as penicillins and cephalosporins. The present invention provides a compound of the formula I EMI1.1 and salts and esters thereof wherein R represents a group R , OR1, 1 or NRARB, where R1, RA and RB independently represent hydrogen, a substituted or unsubstituted hydrocarbon radical, or RA and RB together form the residue of a heterocyclic ring, X represents oxygen or sulphur and R2 is an optionally substituted hydrocarbon or heterocyclic group. The group R2 may for example represent an optionally substituted C16 alkyl group, a C39 cycloalkyl group, or an optionally substituted heteroaryl methyl group. Preferably X is an oxygen atom. Suitably R1 is hydrogen or an unsubstituted or substituted hydrocarbon radical of up to 20 carbon atoms.A preferred aspect of the invention is when X is oxygen, and R represents a group R1. In particular R1 may be a C 1 6 alkyl, C2 6 alkenyl, C26 alkynyl, aryl C1 6 alkyl, aryl C2 6 alkenyl, heteroaryl C1 6 alkyl, C3 8 cycloalkyl, aryl, heteroaryl, C3 8cycloalkyl C1 6 alkyl, heterocyclyl or heterocyclyl C1 6 alkyl group, any of such groups being optionally substituted. Suitably the hetero atom or hetero atoms in the above named heteroaryl and or heterocyclyl moieties are selected from 1 to 4 oxygen, nitrogen or sulphur atoms. Suitable optional substituents for the group R1 include C alkyl, amino, C1 6 alkanoylamino, mono, di and tri C1 6 alkylamino, hydroxy, C16 alkoxy, mercapto, C16 alkylthio, heteroarylthio, arylthio, oxo, sulphamoyl, carbamoyl, amidino, guanidino, nitro, chloro, bromo, fluoro, carboxy and salts and esters thereof, C1 6 alkanoyloxy, arylcarbonyl and heteroarylcarbonyl. Most suitably R1 is a C1 6 alkyl group, for example a methyl, ethyl, propyl or butyl group. Suitably 1 also R1 is a C2 6 alkenyl group such as an allyl group. R1 may also be an aryl C1 6 alkyl group preferably where the aryl group is phenyl, for example phenethyl, benzyl and substituted benzyl where preferably the substituents are hydroxy, acetoxy, amino and carboxy wherein such substituents may be on the ring or the methylene carbon. In an alternative R1 may be an aryl or heteroaryl group such as phenyl or substituted phenyl, for example hydroxyphenyl, chlorophenyl, C1 3 alkylphenyl or C1 3 alkoxyphenyl. Suitably also R may be a C38 cycloalkyl ring such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Suitably the heteroaryl moieties referred to hereinabove contain from 5 to 6 ring atoms attached via a carbon atom to the C X moiety, such as furyl, thienyl, pyridyl and pyrrolyl.Suitably the heterocyclyl moieties referred to hereinabove contain from 4 to 8 ring atoms attached via a carbon atom to the C X moiety, such as azetidine, tetrahydropyran and tetrahydrofuran. In a further aspect it is to be realised that any heteroaryl or aryl moiety may be fused so as to form a bicyclic fused ring system, for example indolyl, naphthyl, benzofuryl and quinolyl. Suitably the group R2 contains from 1 to 14 carbon atoms, in particular from 1 to 8 carbon atoms. The group R2 may be substituted with, for example, halogen, hydroxy, cyano, carboxylic acid, salt or ester, ORC, SRC,CÃ§ 9Rc, OCORC or OCO2RC , where RC is a hydrocarbon group of from 1 to 8 carbon atoms.Suitably R2 is a C16 alkyl group optionally substituted by hydroxy, carboxy or salts or esters thereof, cyano, a heterocyclyl ring bonded via a nitrogen atom, or a group of the sub formula i EMI4.1 wherein R3 is a hydrogen, fluorine, chlorine or bromine atom or a C13 alkyl, C13 alkoxy, C13 alkanoyloxy, hydroxy, C 4 alkoxycarbonyl group, or a group N R6 CoR7, 6 N R6 SO2R7 or CoNR6R7 wherein R6 is a hydrogen atom, C1 3 alkyl, phenyl or benzyl and R7 is C1 3 alkyl, phenyl or benzyl R is a hydrogen, fluorine or chlorine atom or is C 1 3 alkyl, C13 alkoxy or C 1 3 alkanoyloxy and R5 is a hydrogen, fluorine or chlorine atom or a C1 3 alkoxy or alkyl group. Suitably also R2 is a C3 9 cycloalkyl group, for example cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, of these cyclopropyl is favoured. Suitably also R2is an optionally substituted heteroarylmethyl group wherein the heteroaryl moiety is an aromatic monocyclic or bicyclic heterocyclic group bonded via a carbon atom. Suitable aromatic monocyclic heterocyclic groups are those containing 5 or 6 ring atoms.Suitable aromatic bicyclic heterocyclic groups are those having a benzene ring fused to an aromatic heterocyclic group containing 5 or 6 ring atoms. Thus suitable groupsR2 include the furylmethyl, thienylmethyl, pyrrolylmethylN methylpyrrolylmethyl, indolylmethyl, oxazolylmethyl, thiazolylmethyl and quinolylmethyl groups. Suitable substituents include those hereinbefore stated to be suitable for R1. More suitably R2 is a C 6 alkyl group optionally substituted by hydroxy, carboxy or salts or esters thereof or cyano, for example R2 may be C1 6 alkyl either branched or straight chain such as methyl, ethyl,n propyl, isopropyl, n butyl sec butyl, isobutyl, pentyl or hexyl, of these ethyl, n propyl, and isobutyl are favoured with R2 isobutyl being preferred alternatively R2 may be C16 alkyl substituted by carboxy, for example carboxyethyl, carboxypropyl and carboxybutyl, or R2 may be C1 6 alkyl substituted by cyano such as cyanoethyl, or R2 may be C1 6 alkyl substituted by hydroxy such as hydroxyethyl. Suitably also R2 is a C 6 alkyl group, preferably a methyl group substituted by a group of the sub formula i as hereinbefore defined. Thus favoured groups R2 include benzyl and benzyl substituted by one, two or three groups or atoms selected from fluorine, chlorine, bromo, C13 alkyl, C 1 3 alkoxy, hydroxy, C16 alkanoylamino such as acetamido, and C14 alkoxycarbonyl such as methoxycarbonyl. Preferably R2 is benzyl, hydroxybenzyl, acetamidobenzyl and methoxybenzyl. Suitably also R2 is a C 1 6 alkyl group substituted by a heterocyclyl ring bonded via a nitrogen atom to said alkyl group. Suitably the heterocyclyl ring contains 3 to 8 ring atoms, one of which in addition to the above mentioned nitrogen atom may be selected from nitrogen, oxygen or sulphur. Said heterocyclyl ring may be substituted by one or two groups selected from C 6 alkyl, C 1 6 alkoxy, hydroxy, oxo or phenyl. Thus suitable values for R2 include morpholino C16 alkyl such as morpholinopropyl and morpholinoethyl, and pyrrolidino C1 6 alkyl such as pyrrolidinopropyl. Suitably the group NRARB contains up to 16 carbon atoms. Suitable values of RA are as described hereinabove for the group R1. Suitable values of RB are as described hereinabove for the group Rl. A group of compounds of interest is that whereinX is oxygen, and R is hydrogen, C16 alkyl, phenyl, C16 alkylaminocarbonyl, aminocarbonyl or di C16 alkylaminocarbonyl. Another group of compounds of interest is that wherein X is oxygen, and R is C1 6 alkoxy example methoxy or ethoxy, or is phenoxy. A further group of interest is that wherein X is oxygen or sulphur, and R is hydrogen, C1 6 alkyl, C1 6 alkoxy, C1 6 alkylamino or phenyl optionally substituted with up to three substituents selected from C16 alkyl, nitro, halogen or hydroxy. Thus a favoured sub group of compounds of this invention is that of the formula II EMI6.1 and salts and esters thereof wherein R2 is as hereinbefore described. A preferred class of compounds of this invention is that of the formula III EMI7.1 and salts and esters thereof wherein R8 is C36 cycloalkyl, such as cyclopropyl C 1 6 alkyl, such as methyl, ethyl, n propyl, isopropyl, n butyl, sec butyl and isobutyl or carboxy C1 6 alkyl, such as carboxy n propyl. Of these ethyl, n propyl and isobutyl are favoured. Thus particular compounds of this invention include 9 N cyclopropyl formamidodeoxyclavulanic acid, 9 N 3 carboxypropyl formamidodeoxyclavulanic acid, 9 N ethyl formamidodeoxyclavulanic acid, 9 N is obutyl formamidodeoxy clavulanic acid, 9 N isobutyl N ethoxycarbonyl aminodeoxyclavulanic acid, 9 N isobutyl N benzoyl aminodeoxyclavulanic acid, 9 0N isobutyl N methylureido deoxyclavulanic acid, 9 N isobutylureido deoxyclavulanic acid, 9 EN isobutyl N methylthioureidogdeoxyclavulanic acid, and 9 N isobutyl N acetyl aminodeoxyclavulanic acid, and pharmaceutically acceptable salts thereof. The major utility of the compounds of the formulae I III and salts and esters thereof is as pharmaceuticals and accordingly the salts and esters of the compounds of the formulae I III are preferably pharmaceutically acceptable. The compounds of this invention bo Lh pharmaceutically acceptable and non pharmaceutically acceptable may be used as intermediates and also as antibacterial agents or ss lactamase inhibitors in non pharmaceutical usage such as a disinfectant or paint additive. Suitable pharmaceutically acceptable salts of the compounds of the formula I III include metal salts such as aluminium, alkali metal salts such as sodium and potassium, and alkaline earth metal salts such as calcium or magnesium and ammonium and substituted ammonium salts, for example those with lower alkylamines such as triethylamine, cycloalkylamines such as bicyclohexylamine, or with dibenzylamine, N,N dibenzylethyl enediamine, l ephenamine, N ethylpiperidine and N benzyl ss phenethylamine. Suitable esters of the compounds of the formulae I III include those cleavable by biological methods such as enzymatic hydrolysis, in vivo hydrolysis, and those cleavable by chemical methods such as hydrogenolysis, hydrolysis, electrolysis or photolysis. Suitably the carboxylic acid is esterified by a group of the sub formula a , b , c , d , e , or f EMI9.1 wherein A1 is a hydrogen atom, C 1 6 alkanoyl or an C15 alkyl group optionally substituted by C 1 7 alkoxy or C 1 7 carboxylic acyloxy, or an alkenyl or alkynyl group of up to 5 carbon atoms A2 is a hydrogen atom or a methyl group A3 is a phenyl group or a phenyl group substituted by a fluorine, chlorine or bromine atom or a nitro, C1 3 4 alkyl or C1 3 alkoxy group A4 is a hydrogen atom or a phenyl group or phenyl group substituted by a fluorine, chlorine or bromine atom or a nitro, C13 alkyl or C 1 3 alkoxy group A5 is a hydrogen atom or a methyl group A6 5 is a C14 alkyl, phenyl or C 1 4 alkoxy group or A is joined to A6 to form a phthalidyl, dimethylphthalidyl or dimethoxyphthalidyl group A7 is a C1 4 alkyl, or nitrophenyl group A8 is a C1 4 alkyl or phenyl group A9 is a C1 4 alkyl or phenyl group A10 is C1 4 alkyl and A is C1 4 alkyl or CHA A is a phenacyl or bromophenacyl group. Favourably A1is a hydrogen atom or a methyl, ethyl, vinyl or ethenyl group. Favourably A2 is a hydrogen atom. Favourably A3 is a phenyl, p bromophenyl, p methoxyphenyl or p nitrophenyl group. Favourably A4 is a hydrogen atom. Favourably A6 is a methyl, t butyl or ethoxy group or is joined to A5. Favourably A7 is a methyl group. Preferred groups of the sub formula a include the methyl, ethyl and acetonyl groups. Preferred groups of the sub formula b include the benzyl and p nitrobenzyl groups. Preferred groups of the sub formula c include the acetoxymethyl, pivaloyloxymethyl, a ethoxycarbonyloxymethyl and phthalidyl groups. A preferred group of the sub formula d is the methoxymethyl group. Preferred groups of the sub formula e include the trimethylsilyl, tert butyldimethylsilyl and tertbutyldiphenylsilyl groups. A preferred group of the sub formula f is p methoxycarbonylbenzyl. Particularly preferred esterifying groups are the p nitrobenzyl and phthalidyl groups. Pharmaceutically acceptable in vivo hydrolysable esters are those esters which hydrolyse in the human body to produce the parent acid or its salt. Such esters may be identified by administration to a test animal such as a rat or mouse by intravenous administration and thereafter examining the test animal s body fluids for the presence of the compound of the formulae I III or salt. Suitable esters of this type include those of sub formula c as hereinbefore defined. Further suitable esters include di C1 6 alkylamino C 1 6 alkyl esters such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl and diethylumino ethyl. Esters of the compounds of the formulae I III such as those of the sub formula a f if desired, may be presented in the form of their acid addition salts if an amino group is present in either of groups R1 or R2.The acid used to form the salt will most suitably be pharmaceutically acceptable, but non pharmaceutically acceptable acid addition salts are also envisaged, for example as intermediates in the preparation of the pharmaceutically acceptable salts by ion exchange. Suitable pharmaceutically acceptable acid addition salts include those of inorganic and organic acids, such as hydrochloric, phosphoric, sulphuric, methanesulphonic, toluenesulphonic, citric, malic, acetic, lactic, tartaric, propionic and succinic acid. Most suitably the acid addition salt is provided as a solid and preferably as a crystalline solid. Compounds of this invention when in crystalline form may be solvated, for example hydrated. The present invention provides a pharmaceutical composition which comprises a compound of this invention and a pharmaceutically acceptable carrier. The compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of the infection in animals for example mammals including humans. Suitable forms of the compositions of this invention include tablets, capsules, creams, syrups, suspensions, solutions, reconstitutable powders and sterile forms suitable for injection or infusion. Such compositions may contain conventional pharmaceutically acceptable materials such as diluents, binders, colours, flavours, preservatives, disintegrant and the like in accordance with conventional pharmaceutical practice in the manner well understood by those skilled in the art of formulating antibiotics. Injectable or infusable compositions of a compound of the invention are particularly suitable as high blood levels of the compound can occur after administration by injection or infusion. Thus, one preferred composition aspect of this invention comprises a compound of the invention in sterile form and most suitably in sterile crystalline form. The injectable solution of the compound of this invention may be made up in a sterile pyrogen free liquid such as water, aqueous ethanol or the like. An alternative approach to administering the compounds of this invention is to utilise an injectable suspension. Such suspensions may be made up in sterile water sterile saline or the like, and may also contain suspending agents such as polyvinylpyrrolidone, lecithin or the like. Alternatively such compositions may be prepared in an acceptable oil suspending agent such as arachis oil or its equivalent. For use in such suspensions the compounds of this invention should be in the form of fine particles. Unit dose compositions comprising a compound of this invention adapted for oral administration form a further suitable composition aspect of this invention. Unit dose compositions comprising a compound of this invention adapted for topical administration are also presented by this invention. In this instance topical administration also includes local administration to internal surfaces of mammary glands of cattle, for example during the treatment of mastitis by intra mammary administration. The compound of the formula may be present in the composition as sole therapeutic agent or it may be present together with other therapeutic agents such as a penicillin or cephalosporin. Considerable advantages accrue from the inclusion of a penicillin or cephalosporin which shows instability to S lactamasessince the resulting composition shows enhanced efectiveness synergy . Suitable penicillins, cephalosporins or otherB lactam antibiotics for inclusion in such synergistic compositions include not only those known to be highly susceptible to 8 lactamases but also those which have a degree of intrinsic resistance to B lactamases. Suitable penicillins for inclusion in the compositions of this invention include benzylpenicillin, phenoxymethylpenicillin, carbenicillin, azidocillin, propicillin, ampicillin, amoxycillin, epicillin, ticarcillin, cyclacillin, pirbenicillin, azlocillin, mezlocillin, sulbenicillin, piperacillin, and other known penicillins including pro drugs therefor such as their in vivo hydrolysable esters such as the acetoxymethyl, pivaloyloxymethyl, o ethoxycarbonyloxyethyl or phthalidyl esters of ampicillin, benzylpenicillin or amoxycillin, and aldehyde or ketone adducts of penicillins containing a 6 a aminoacetamido side chain such as hetacillin, metampicillin and analogous derivatives of amoxycillin or esters of carbenicillin or ticarcillin such as their phenyl or indanyl a esters. Suitable cephalosporins for inclusion in the compositions of this invention include cefatrizine, cephaloridine, cephalothin, cefazolin, cephalexin, cephacetrile, cephamandole nafate, cephapirin, cephradine, 4 hydroxycephalexin, cefaparole, cephaloglycin, cefoperazone and other known cephalosporins or pro drugs thereof. Such compounds are frequently used in the form of a salt or hydrate of the like. Naturally if the penicillin or cephalosporin present in the composition is not suitable for oral administration then the composition will be adapted for parenteral administration. Highly favoured penicillins for use in the compositions of this invention include ampicillin, amoxycillin, carbenicillin and ticarcillin. Such penicillins may be used as a pharmaceutically acceptable salt such as the sodium salt. Alternatively the ampicillin or amoxycillin may be used in the form of fine particules of the zwitterionic form generally as ampicillin trihydrate or amoxycillin trihydrate for use in an injectable suspension, for example in the manner hereinbefore described for a compound of this invention. The preferred penicillin for use in the synergistic composition is amoxycillin, for example as its sodium salt or trihydrate. Particularly suitable cephalosporins for use in the compositions of this invention include cephaloridine and cefazolin which may be in the form of a pharmaceutically acceptable salt for example the sodium salt. When present together with a cephalosporin or penicillin, the ratio of a compound of the invention to the penicillin or cephalosporin agent may vary over a wide range of ratios, such as from 10 1 to 1 10 for example about 3 1, 2 1, 1 1, 1 2, 1 3, 1 4, 1 5 or 1 6, wt wt, based on pure free antibiotic equivalent . Orally administrable compositions containing a compound of the invention will normally contain relatively more synergist than corresponding injectable compositions. The total quantity of a compound of the invention in any unit dosage form will normally be between 25 and 1000 mg and will usually be between 50 and 500 mg, for example about 62.5, 100, 125, 150, 200 or 250 mg. Compositions of this invention may be used for the treatment of infections of inter alia the respiratory tract, the urinary tract and soft tissues in humans and mastitis in cattle. Normally between 50 and 3000 mg of the compounds of the invention will be administrered each day of treatment but more usually between 100 and 1000 mg of the compounds of the invention will be administered per day, for example at 1 6 doses, more usually as 2, 3 or 4 doses.However, for the treatment of more severe systemic infections or infections of particularly intransigent organisms higher doses may be used in accordance with clinical practice. The penicillin or cephalosporin in the synergistic composition of this invention will normally be present at approximately the amount at which it is conventionally used which will usually be expected to be from about 62.5 to 3000 mg per dose, more usually about 125, 250, 500 or 1000 mg per dose. One particularly favoured composition of this invention will contain from 150 to 1000 mg of amoxycillin as the trihydrate or sodium salt and from 25 to 500 mg of a compound of this invention. A further particularly favoured composition of this invention will contain from 150 to 1000 mg of ampicillin or a pro drug therefor and from 25 to 500 mg of a compound of this invention. Most suitably this form of composition will contain ampicillin trihydrate, ampicillin anhydrate, sodium ampicillin, hetacillin, pivampicillinhydrochloride, bacampicillin hydrochloride, or talampicillin hydrochloride.Most suitably this form of the composition will contain a compound of this invention when in crystalline form. Most suitably the preceding composition will contain from 200 to 700 mg of the penicillin component.Most suitably the preceding composition will comprise from 50 to 250 mg of a compound of this invention preferably in crystalline form. Such compositions may be adapted for oral or parenteral use except when containing an in vivo hydrolysable ester of ampicillin or amoxycillin in which case the compositions will not be adapted for parenteral administration. Another particularly favoured composition of this invention will contain from 200 to 2000 mg of carbenicillin, ticarcillin or a pro drug therefo and from 50 to 500 mg of a compound of the invention. Suitably this form of composition will contain di sodium carbenicillin. Suitably this form of the composition will contain di sodium ticarcillin. More suitably this form of the composition will contain from 75 to 250 mg of a compound of this invention preferably in crystalline form. Such compositions containing di salts of carbenicllin and ticarcillin will be adapted for parenteral administration. The present invention also provides a method of treating bacterial infections in humans or domestic mammals which comprises the administration of a composition of this invention. Commonly the infection treated will be due to a strain of Staphylococcus aureus, Klebsiella aeroqenes,Escherichia coli, Proteus sp., Bacteroides fraqilis or the like. The organisms believed to be most readily treated by an anti bacterially effective amount of a compound of this invention is Staphylococcus aureus.The other organisms named are more readily treated by using a synergistically effective amount of the compound of the invention and a penicillin or cephalosporin.The administration of the two components may take place separately but in general we prefer to use a composition containing both the synergist and the penicillin or cephalosporin. The indications for treatment include respiratory tract and urinary tract infections in humans and mastitis in cattle. The present invention also provides a process for the preparation of a compound of the formula I or a salt or ester thereof, which process comprises the reaction of a compound of the formula IV EMI19.1 wherein R2 is as hereinbefore defined and Ra is a hydrogen atom or a carboxy blocking group with anN acylating derivative of an acid of formulaEMI19.2 wherein R and X are as hereinbefore defined and optionally thereafter i removing any carboxy blocking group Ra, ii converting the product into a salt or ester, Suitable N acylating derivatives include anyN acylating compound suitable for the performance of analogous reactions with 6 aminopenicillanic acid or 7 aminocephalosporanic acid or salts or esters thereof, for example an acid halide, an anhydride or mixed anhydride or other reactive derivative, such as that produced by the reaction of an acid with an enzyme or a condensation promoting agent such as dicyclohexylcarbodiimide. Suitably the N acylating derivative is a compound of the formula V EMI19.3 wherein R1 and X are as hereinbefore defined, and Y is a readily displaceable group. Suitably Y is halo such as chloro or bromo, or a sulphonyloxy moiety, for example C16 alkyl or arylsulphonyloxy, such as a mesylate or a tosylate, or Y is a carboxylate moiety, for example a C1 6 alkanoyloxy group optionally substituted by 1 to 3 halogen atoms, in particular acetoxy, dichloroacetoxy and trichloroacetoxy, or an arylcarbonyloxy moiety for example benzoyloxy. Alternatively Y is a hydroxy group or hydrocarbyloxy group, for example C16 alkoxy or aryloxy such as phenoxy. Preferably the reaction is performed in the presence of a base, for example an inorganic base such as an alkali or alkaline earth metal salt, in particular lithium, sodium or potassium carbonates or an organic base such as an amine, for example a tertiary amine and in particular triethylamine. Suitably the reaction is performed in an aprotic organic solvent such as dimethylformamide, acetonitrile, ethyl acetate, dimethyl sulphoxide, diethyl ether, tetrahydrofuran, dichloromethane, chloroform or mixtures thereof. Water may be added to aid solubility, a particularly preferred solvent mixture is aqueous dimethylformamide. The reaction is suitably performed at a non extreme temperature, for example between 200C and 400C and preferably at ambient. Alternatively when it is desired to form a compound wherein R represents a group NRARB, suitable acylating agents include isocyanates and thioisocyanates, preferably such reaction is performed in an aprotic solvent at a non extreme temperature. Suitable carboxyl blocking derivatives for the group CO2Ra in formulae IV include salts, esters, and anhydride derivatives of the carboxylic acid. The derivative is one which may readily be cleaved at a later stage of the reaction. The salts need not be pharmaceutically acceptable. Suitable salts include inorganic salts, for example metal salts such as silver or mercuric salt, or alkali metal salts such as the lithium or sodium salt, and tertiary amine salts. Suitable ester forng. carboxyl blocki ng.grtups are those which may be removed under conventional conditions, and include those of sub formulae a .f as hereinbefore defined. Such groups for Ra include benzyl, p methoxybenzyl, 2,4 ,6 trimethylbenzyl, 3,5 dit butyl 4 hydroxybenzyl, benzoylmethyl, p nitrobenzyl, 4 pyridyl methyl, 2,2,2 trichloroethyl, 2,2,2 tribromoethyl, acetonyl, 2 methylallyl, t butyl, t amyl, diphenylmethyl, triphenylmethyl, methyl, ethyl, allyl, adamantyl, 2 benzyloxyphenyl, 4 methylthiophenyl, tetrahydrofur2 yl, tetrahydropyran 2 yl, methoxymethyl, a silyl, stannyl or phosphorus containing group, or an in vivo hydrolysable ester. The carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular Ra group, for example, acid and base catalysed hydrolysis, or by enzymically catalysed hydrolysis, photolysis or by hydrogenation. The hydrolysis must of course be carried out under conditions to which the groups on the rest of the molecule are stable. When it is desired to produce a compound of formula I in the form of a free acid or salt by the process of this invention, a compound of formula IV is generally employed wherein Ra is a carboxyl blocking group. For the preparation of a compound of formula I in the form of a pharmaceutically acceptable ester, it is convenient to employ a compound of formula IV wherein Ra represents the desired ester group. The compounds of the formula IV may be prepared by the methods of European Patent Application PublicationNumbers 5014, 7717, 9302, 8884, 21836, 25271, 27323, 27324 and Belgian Patent Number 866276. The following Examples illustrate the invention. Example 1Lithium 9 1 cyclopropyl formamidodeoxyclavulanate EMI23.1 9 N Cyclopropylaminodeoxyclavulanic acid 1.1 1g 5.24 mmol in dimethylformamide 20 cm3 and water 12 cm3 was treated with 1 2 equivalent lithium carbonate 0.193g followed by 1.2 equivalents of phenyl formate and the mixture stirred at room temperature for five hours. The reaction mixture was allowed to stand at 10 for 15 hours after which the solvent was removed by evaporation under high vacuum. The residue was chromatographed on silica eluting with ethylacetate isopropylalcohol water 5 4 2 and fractions containing the title compound collected Rf SiO2 solvent system as above 0.61.Combined fractions were evaporated and triturated with acetone to afford a white solid, yield 0.63g 44 .u nujol 1785, 1660, 1620, 1305, 1190, 1120, 1040, 900, 740 cm u KBr 1788, 1680 very broad , 1400, 1360, 1308, 1190, 1118, 1040, 1027, 900, 740 cm S D20 0.58 0.88 4H, m,EMI23.2 2.53 2.83 1H, m,EMI23.3 3.01 1H, d, J 17 Hz, 6CH , 3.51 1H, dd, J 17 and 3 Hz, 6aCH , 3.83 4.03 2H, m, 9CH2 , 8CH obscured by HOD, 4.87 1H, broad s, 3CH , 5.65 1H, d, J 3 Hz, SaCH , 7.99 and 8.07 1H, 2 x s, NCHO . Example 2Dilituium 9 3 carboxypropyl 1 formamidodeoxyclavulanateEMI25.1 9 N 3 Carboxypropyl aminodeoxyclavulanic acid 0.528g 1.87 mmol in dimethylformamide 10 cm3 and water 7 cm3 was treated with one equivalent 138 mg of lithium carbonate with stirring, followed by phenyl formate 12.2 equivalents . The mixture was stirred for 26 hours, when the solvent was evaporated under high vacuum and the residue chromatographed on silica eluting with ethylacetate ethanol water 5 3 2 . Fractions were collected containing the title compound Rf SiO2 ethylacetate ethanol water 5 3 2 0.6. Combined fractions were evaporated and on addition of ethanol a white solid formed.This solid was filtered off cold, washed with cold ethanol and dried to afford 230 mg 38 of a white solid. nujol 1785, 1650 very broad . w KBr 1786, 1645 vbr , 1400, 1305, 1187, 1115, 1040, 1015, 895 cm 1. D20 1.55 1.95 2H, broad m, NCH2CH2CH2CO2 , 2.13 2H, broad t, J 6.5 Hz, NCH2CH2CH2C02 , 3.00 1H, d, J 17 Hz, 6 beta CH , 3.08 3.35 2H, broad m,NCH2CH2CH2 , 3.50 1H, dd, J 17 and 3 Hz, 6 alpha CH , 3.92 2H, broad d, J 7 Hz, 9CH2 , 4.72 1H, broad t,J 7 Hz, 8CH , 4.88 1H, s, 3CH, 5.68 1H, broad d, J 3 Hz, SaCH , 7.89 and 7.96 1H, 2 x s, NCHO . Example 3Lithium 9 N ethyl formamidodeoxyclavulanate EMI27.1 9 N Ethylaminodeoxyclavulanic acid 1.29g 5.70 mmol in dimethylformamide 20 cm3 and water 10 cm3 was treated with 1 2 equivalent of lithium carbonate followed by 1.2 equivalents of phenyl formate and stirred for 24 hours. The solvent was removed under high vacuum and the residue chromatographed on silica eluting with ethyl acetate ethanol water 5 3 3 and fractions containing the title compound were collected Rf SiO2 ethylacetate isopropylalcohol water 5 4 2 0.5 detection by aqueous potassium permanganate spray . Combined fractions were evaporated to an oil, triturated with acetone and filtered off. Drying afforded 720 mg 49 of a white solid. o nujol 1785, 1655, 1615, 1300, 1190, 1115, 1080, 1035, 1015, 895 cm S D20 1.03 and 1.11 3H, 2 x t, J 7Hz, NCH2CH3 , 3.03 1H, d, J 17Hz, 66CH , 3.18 3.40 2H, m, NCH2CH2 , 3.52 1H, dd, J 17 and 3Hz, 6aCH , 3.95 2H, d, J 7Hz, 9CH2 , 4.74 1H, broad t, J 7Hz, 8CH , 4.88 1H, broad s, 3CH , 5.69 1H, d, J 3 Hz, SaCH , 7.95 1H, s, NCHO . Example 4Lithium 9 N isobutyl formamidodeoxyclavulanateEMI28.1 A suspension of 9 N isobutylaminodeoxyclavulanic acid 254 mg 1 mmol in dimethylformamide 10 ml was treated with a solution of lithium carbonate 37 mg 0.5 mmol followed by phenyl formate 134 yl 1.2 mmol the resulting solution was stirred at room temperature for 8 hours. The dimethylformamide was removed in vacuo and the residual solid was fractionated on silica using ethyl acetate propan 2 ol water 5 4 2 as eluent.Fractions containing the required product, Rf SiO2 ethyl acetate propan 2 ol water 5 4 2 0.61, were combined and evaporated in vacuo the title compound was obtained as a colourless crystalline solid from acetone.Yield 73 . omax Nujol 1785, 1690 sh , 1600 1660 cm 1 omax KBr 1785, 1685 sh , 1675, 1658, 1615 cm . 6 D20 0.79 6H, d, J 7Hz, CH CH, 2 , 2.0 1H, m, CH CH3 2 , 3.0 1H, d, J 17 Hz, 6ss CH , 3.03 2H, d, J 7Hz, CH2 CH CH3 2 , 3.53 1H, dd, J 17 and 3 Hz, 6a CH , 3.96 2H, d, J 7 Hz, 9 CH2 , 4.68 1H, m, 8 CH , 4.88 1H, d, J 1.5 Hz, 3 CH , 5.69 1H, d, J 3Hz, 5 CH , 7.93, 8.08 1H, both singlets,N.CHO . Example 5Lithium 9 N isobutyl N ethoxycarbonyl amino deoxyclavulanateEMI29.1 To a solution of 9 N isobutylaminodeoxyclavulanic acid 0.8g 3 mmol in dimethylformamide 15 ml and water 12 ml at 0 C was added lithium carbonate 0.12g and ethyl chloroformate 0.31 ml 3.2 mmol .The reaction mixture was stirred at 0 C for 2i hours then poured on to water 70 ml . The aqueous layer was washed with ethyl acetate 2 x 70 ml and the solvent removed under reduced pressure to give an off white solid. This solid was chromatographed on silica, eluting with ethyl acetate ethanol water 4 1 , and the fractions containing the required product, Rf. 0.34, ethyl acetate ethanol water 4 1 were combined and evaporated in vacuo the title compound was obtained as a white solid after precipitation from acetone with ether, 0.73g, 72 . Nmax KBr . 1790, 1680 broad , 1600 broad cm 1. SH D2O , 5.66 1H, d, J 3Hz, H C5 , 4.85 1H, S, H C3 , 4.75 1H, broad t, J 7Hz, H C8 , 4.05 2H, Q, J 7Hz,OCH2CH3 , 3.89 2H, d, J 7 Hz, H2 C9 , 3.55 1H, dd, J 3Hz and 17 Hz, alpha H C6 , 3.02 2H, d, J 7Hz, CH2CH CH3 2 , 2.95 1H, d, J 17Hz, ssH C6 , 1.85 1H, broad m, CH CH3 2 , 1.22 3H, t, J 7Hz, OCH2CH3 0.83 6H, d, J 7Hz,CH CH3 2 . Example 6Benzyl 9 N isobutyl N benzoyl aminodeoxyclavulanateEMI31.1 Lithium 9 N isobutyl N benzoylaminodeoxy clavulanate 0.12g 3 mmol and benzyl bromide 0.04 ml., 3.4 mmol were dissolved in dimethylformamide 5 ml and stirred at room temperature for 7 hours. The reaction mixture was then poured on to ethyl acetate 30 ml and the resulting organic layer washed with water 2 x 30 ml and saturated sodium chloride solution 30 ml before being dried over anhydrous magnesium sulphate. Removal of the solvent under reduced pressure yielded a colourless oil which was chromatographed on silica, eluting with ethyl acetate cyclohexane 1 1 .The fractions containing the component of Rf ethyl acetate cyclohexane 1 1 0.46 were combined and the solvent removed under reduced pressure to yield the title compound as a colourless oil 0.05g, 33 . y max CHCl3 1800, 1750, 1690, 1620 cm 1. 6 550CH C CDCl3 7.30 10 H, S, CH2 Ph and COPh , 5.56 1H, d, J 3Hz, H C5 , 5.16 2H, S, CH2Ph , 5.02 1H, S,H C3 , 4.66 1H, broad t, J 7Hz, H C8 , 4.02 2H, d, J 7Hz, H2 C9 , 3.44 1H, dd, J 3Hz and 17 Hz, alpha H C6 , 3.10 2H, d, J 7Hz, CH2CH CH3 2 , 2.88 1H, d, J 17Hz, beta C6 , 1.95 1H, broad m, CH CH3 2 , 0.77 6H, d, J 7Hz,CH CH3 2 . Example 7Lithium 9 N isobutyl N methylureido deoxyclavulanateEMI33.1 9 N isobutylaminodeoxyclavulanic acid 0.2g 0.8 mmol , was stirred at room temperature in dimethylformamide 10 ml containing water 5 ml and lithium carbonate 0.03 g for 1 4 hr. The reaction mixture was then filtered, and the filtrate evaporated in vacuo to yield lithium 9 N isobutylaminodeoxyclavulanate 0.18 g as a pale yellow solid, crystallised from acetone as colourless crystals. 0.16 g . To lithium 9 N isobutylaminodeoxyclavulanate 0.16g 0.6 mmol in dry redistilled dimethylformamide 10 ml was added methylisocyanate 0.04g, 0.7 mmol .The reaction mixture was stirred at room temperature for 3 hours, then poured on to water 20 ml . The aqueous layer was washed with ethyl acetate 2 x 30 ml and then the water removed in vacuo to give a pale yellowfoam.The foam was chromatographed on silica, eluting with ethyl acetate ethanol water 6 4 i . The fractions containing the title compound, Rf ethyl acetate ethanol water 5 4 i 0.46, were combined and the solvent removed under reduced pressure to give a pale yellow glass, which gave rise to a white solid when precipitated from acetone by the addition of ether 0.1 g 42 . max Nujol , 1790, 1690 sh , 1620 cm 1. H D2O 5.66 1H, d, J 3Hz, H C5 , 4.85 1H, S, H C3 2H, d, J 7Hz, H2 C9 , 3.51 1H, dd, J 3Hz and 17 Hz, aH C6 , 2.99 1H, d, J 17Hz, ssH C6 , 2.95 2H, d, J 7 Hz, CH2CH CH3 2 , 2.62 3H,S, N CH3 , 1.85 1H, broad, CH CH3 2 , 0.80 6H, d,J 7Hz, CH CH3 2 . Example 8Lithium 9 N isobutyl N benzoyl aminodeoxyclavulanate EMI35.1 9 N isobutylaminodeoxyclavulanic acid 0.5g, 1.9 mmol was dissolved in dimethylformamide 25 ml containing water 15 ml and lithium carbonate 0.07g .After stirring at room temperature for 1 4 hour the reaction mixture was cooled to 0 C in an ice bath and a further portion of lithium carbonate 0.07g added followed by benzoic anhydride 0.45g, 2 mmol . The reaction mixture was stirred at OOC for a further 1 hours, then the dimethylformamide was removed under reduced pressure to yield a yellow brown solid. The solid was chromatographed on silica, eluting with ethyl acetate ethanol water 8 2 1 . Fractions containing the required product, Rf Si02 ethyl acetate ethanol water, 5 4 0.7, were combined and the solvent removed under reduced pressure.The rotational isomers of the title compound were obtained as a white solid by precipitation from acetone with ether 0.49g, 68 . ymax KBr . 1785, 1690 sh , 1600 cm 1, Nujol 1785, 1790, 1610 cm 1. H35 C D2O , 7.34 5H, m, NCOPh. , 5.68 and 5.44 1H, 2 x d, J 3Hz, H C5 , 4.90 and 4.72 1H, 2 x s, H C3 , 4.12 and 3.85 2H, 2 x d, J 7Hz, H2 C9 , 3.50 and 3.40 1H, 2 x dd, J 3Hz and 17 Hz, aH C6 , 3.25 and 3.02 2H, 2 x d, J 7HzCH2 CH3 2X, 2.94 and 2.72 1H, 2 x d, J 17Hz, ssH C6 , 1.95 1H, broad m,CH CH3 2 , 0.9 and 0.6 6H, 2 x d, J 7Hz, CH CH3 2 . Example 9 Lithium 9 N isobutyl N acetyl aminodeoxyclavulanate EMI37.1 9 N isobutylaminodeoxyclavulanic acid 0.34g 1.3 mmol was stirred at room temperature in dimethylformamide 10 ml containing water 5 ml and lithium carbonate 0.05g, 0.6 mmol .The mixture was stirred at room temperature for 1 4 hour, then filtered and evaporated in vacuo to yield lithium 9 N isobutylaminodeoxyclavulanate as a white solid which was crystallised from acetone 0.29 g.83 . To a suspension of lithium 9 N isobutylaminodeoxyclavulanate 0.29g 1.1 mmol in dry redistilled dimethylformamide 10 ml was added acetic anhydride 0.12 ml 1.2 mmol and lithium carbonate 0.04g 0.5 mmol . The reaction mixture was stirred at room temperature for i hour, then evaporated in vacuo to give a pale yellow solid. The solid was subjected to silica gel column chromatography, eluting with ethyl acetate ethanol water 6 4 . The fractions containing the desired product, Rf ethyl acetate ethanol water, 5 4 1 0.65 were combined and the solvent removed under reduced pressure to yield the title compound as a colourless glass obtained as a white solid when precipitated from acetone by the addition of ether 0.22g, 73 . max Nujol 1790, 1690 and 1610 cm 1, CHCl3 1790, 1690, 1610 cm 1. g D20 0.80, 0.86 3H, 2 x d, J 7Hz, CH CH3 2 , 1.90 1H, m, CH CH3 2 , 2.06 and 2.06 3H, 2 x s, COCH3 3.02 1H, d, J 17Hz, 6 CH, 3.10 3.15 2H, 2 x d,J 7Hz, CH2CH CH3 2 , 3.55 1H, dd, J 3 and 17 Hz, 6 aCH 4.0, 4.05 2H, m, 9 CH2 , 4.87 1H, m, 3 CH , 5.70 1H, m, 5 CH . Example 10Lithium 9 N N isobutyl N methylthioureido deoxyclavulanateEMI39.1 9 N isobutylaminodeoxyclavulanic acid 0.51g 2.0 mmol was stirred at room temperature in dimethylformamide 10 ml containing water 10 ml and lithium carbonate 0.077g 0.98 mmol for 1 4 hour. The reaction mixture was then filtered and evaporated in vacuo to give lithium 9 N isobutylaminodeoxy clavulanate, crystallised from acetone as colourless needles 0.49g, 95 . To a stirred suspension of lithium 9 N isobutylaminodeoxyclavulanate 0.24g, 0.92 mmol in dry redistilled dimethylformamide 15 ml at room temperature was added methylisothiocynate 0.07g, 0.95 mmol . The reaction mixture was stirred at room temperature for 24 hours then poured on to water 50 ml . The aqueous layer was washed with ethyl acetate 2 x 60 ml then evaporated in vacuo to yield a yellow glass. This glass was subjected to silica gel column chromatography eluting with ethyl acetate ethanol water 5 1 , combining fraction Rf 0.58 ethyl acetate ethanol water 2 1 and removal of the solvent gave a pale yellow glass which yielded the title compound as an off white solid when precipitated from acetone by addition of ether 0.15 q, 53 . max CHCl3 1790, 1660 and 1610 cm 1. D20 0.86 6H, d, J 7Hz, CH CH3 2 , 2.0 1H, m, CH CH3 2 , 2.49 3H, s, CH3N EMI40.1 3.02 1H, d, J 17Hz, 6ss CH , 3.36 2H,d, J 7Hz, CH2CH CH3 2 , 3.54 1H, dd, J3 and 17 Hz, 6 alpha CH 4.27 2H, m, 9 CH2 , 4.87 1H, s, 3 CH , 5.68 1H, d, J 3 Hz, 5 CH . BIOLOGICAL DATAIn a standard MIC synergy test, the following data were obtained for the compounds of this invention.EMI41.1 tb Amoxycillin SEP SEP MIC SEP pg ml SEP amoxycillin tb the SEP compound SEP of tb SEP Example SEP at SEP Staph. SEP Kleb. SEP Escherichia tb SEP aureus SEP aerogenes SEP coli tb SEP Yg ml SEP Russell SEP E70 SEP JT39 tb SEP 4 SEP 5.0 SEP 0.3 SEP 50 SEP 62.5 tb SEP 1.0 SEP 0.6 SEP 100 SEP 500 tb SEP 2 SEP 5.0 SEP 0.3 SEP 100 SEP 500 tb SEP 1.0 SEP 0.6 SEP 100 SEP 500 tb SEP 3 SEP 5.0 SEP 0.08 SEP 3.1 SEP 2.0 tb SEP 1.0 SEP 0.6 SEP 12.5 SEP 16.0 tb SEP 1 SEP 5.0 SEP 0.08 SEP 3.1 SEP 8.0 tb SEP 1,I SEP 0.3 SEP 12.5 SEP 31.2 tb SEP 5 SEP 5.0 SEP 0.04 SEP 100 SEP 250 tb SEP 1.0 SEP 0.4 SEP 100 SEP 250 tb SEP 8 SEP 5.0 SEP SEP SEP 100 SEP 125 tb SEP 1.0 SEP 0.3 SEP 100 SEP 500 tb SEP 7 SEP 5.0 SEP 0.16 SEP 50 SEP 31.2 tb SEP 1.0 SEP 0.6 SEP 100 SEP 500 tb Amoxycillin SEP 500 SEP 1000 SEP 2000 tb alone tb